Literature DB >> 10197764

Analysis of synaptotagmin I-IV messenger RNA expression and developmental regulation in the rat hypothalamus and pituitary.

D Xi1, H Chin, H Gainer.   

Abstract

Synaptotagmins are a large family of synaptic vesicle membrane proteins, that appear to be involved in neurotransmitter secretion from small secretory vesicles. We have quantitatively analysed the messenger RNA levels of synaptotagmin I-IV isoforms in adult hypothalamic and pituitary tissues in order to determine which of these isoforms dominate in these tissues which mainly secrete peptides from large dense core vesicles. We also studied the expression of these isoforms during prenatal (E15, and E17) and postnatal (P1, P7, P14 and P21) rat hypothalamic development. In order to assay small individual samples (e.g., pituitary and embryonic tissues), we employed quantitative reverse transcription-polymerase chain reaction methods. Our results show that synaptotagmin I messenger RNA is the most abundant isoform in all tissues, and is about 5.4- or 38-fold higher in hypothalamus than in neurointermediate and anterior pituitary lobe, respectively. Synaptotagmin II, which is very abundant in cerebellum, is relatively low in hypothalamus (5% of cerebellum) and virtually absent from the pituitary. Synaptotagmin III is about 10 times greater in the neural tissues versus the pituitary, and synaptotagmin IV was the least abundant isoform in all the tissues. Developmental analyses of the synaptotagmin isoforms in rat hypothalamus shows that all isoforms are at low levels during embryonic stages and increase postnatally. Synaptotagmin I and II have similar patterns and rise to maximum (adult) levels around P14, whereas synaptotagmin III and IV reach their maximum levels considerably earlier, at P1. These data show that synaptotagmin I is the dominant isoform in both predominantly peptide secreting systems (e.g., in pituitary tissues) and in neurotransmitter secreting systems (e.g., in cerebellum). While the developmental expression patterns of synaptotagmin I and II parallels the temporal development of synaptogenesis in the nervous system, the early maximal expression of synaptotagmin III and IV suggests that these isoforms may have other functions during early postnatal development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10197764     DOI: 10.1016/s0306-4522(98)00234-6

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  6 in total

Review 1.  Molecular underpinnings of synaptic vesicle pool heterogeneity.

Authors:  Devon C Crawford; Ege T Kavalali
Journal:  Traffic       Date:  2015-04       Impact factor: 6.215

2.  Chemopreventive Effects of Korean Angelica versus Its Major Pyranocoumarins on Two Lineages of Transgenic Adenocarcinoma of Mouse Prostate Carcinogenesis.

Authors:  Su-Ni Tang; Jinhui Zhang; Wei Wu; Peixin Jiang; Manohar Puppala; Yong Zhang; Chengguo Xing; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-26

3.  Expression of the synaptotagmin I gene is enhanced by binding of the pituitary-specific transcription factor, POU1F1.

Authors:  Paul W Howard; Shall F Jue; Richard A Maurer
Journal:  Mol Endocrinol       Date:  2009-07-16

4.  Molecular cloning and expression analysis of the synaptotagmin-1 gene in the hypothalamus and pituitary of Huoyan goose during different stages of the egg-laying cycle.

Authors:  Xinhong Luan; Lina Luo; Zhongzan Cao; Rongrong Li; Dawei Liu; Ming Gao; Mei Liu; Laiyou Wang
Journal:  Reprod Biol Endocrinol       Date:  2014-08-21       Impact factor: 5.211

5.  Synaptic protein and pan-neuronal gene expression and their regulation by Dicer-dependent mechanisms differ between neurons and neuroendocrine cells.

Authors:  Jutta Stubbusch; Priyanka Narasimhan; Katrin Huber; Klaus Unsicker; Hermann Rohrer; Uwe Ernsberger
Journal:  Neural Dev       Date:  2013-08-20       Impact factor: 3.842

Review 6.  The functional significance of synaptotagmin diversity in neuroendocrine secretion.

Authors:  Paanteha K Moghadam; Meyer B Jackson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-09-18       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.